New investments and operational flexibility at Teknova will be paramount during continued company growth
HOLLISTER, Calif., May 6, 2021 - Teknova, a leading manufacturer of cell culture media and supplements, protein purification buffers, and molecular biology reagents, announced today that Matt Lowell has joined the company as Chief Financial Officer (CFO). Lowell brings with him nearly 20 years of financial and strategic leadership experience in the medical device industry. From 2013 Lowell was Vice President of Finance at Varian Medical Systems, and then Vice President of Finance at Varex Imaging Corporation, having co-led its spinoff from Varian Medical Systems in 2017. Prior to Varian, Lowell held various strategy, business development, and finance roles at Abbott Medical Optics and its predecessor company.
Lowell will use his extensive experience working within complex organizations to provide financial leadership during the company’s current period of rapid growth and transformation. About his new role, Lowell said, “It’s truly exciting to join Teknova just as the company is entering its next phase of development, expanding its commercial channels, creating new products, and substantially expanding its production capabilities. Developing scalable infrastructure will be critical to the Company’s success as it grows. I’ll plan to do my part by setting stretch financial goals, helping the company to make sound investments, and ensuring that we have the financial planning, reporting, and analytical tools we need to make well informed business decisions. I look forward to contributing all I can to Teknova’s success.”
In addition to leading Teknova’s core finance functions, such as accounting, financial planning and analysis, reporting, and cash management, Lowell will play a leadership role in raising new capital and executing on potential partnership and acquisition opportunities.
Teknova CEO Stephen Gunstream said, “It’s great to have Matt on board. His experience, strategic acumen, and financial expertise will be extremely valuable. Matt shares our vision for the future of Teknova, and we are delighted to welcome him to the team.”
Teknova is expediting clinical breakthroughs in the life sciences by providing custom products and reagents for bioprocessing, bioproduction, and molecular diagnostics. With a focus on agility and customization, Teknova delivers research-grade and GMP products including cell culture media and supplements, protein and nucleic acid purification buffers, and molecular biology reagents for a multitude of established and emerging applications, including cell and gene therapy, mRNA therapeutics, genomics, and synthetic biology. Teknova's proprietary processes enable the manufacture and delivery of high quality, custom, made-to-order products on short turnaround times and at scale, across all stages of development, including commercialization.
Chief Financial Officer
+1 831 216-1830